U.S. Plant-Based Biologics Market 2022-2030 Latest News

This Plant-Based Biologics Market research report contains a complete background analysis of the industry, which includes an assessment of the parental market. All the statistical and numerical that have been forecasted in this report is represented with the help of graphs, charts, or tables which makes this report more user-friendly. This Plant-Based Biologics Market report contains a thorough description, competitive scenario, wide product portfolio of key vendors, and business strategy adopted by competitors along with their SWOT analysis and porter’s five force analysis. Whether it is about renewing a business plan, preparing a presentation for a key client, or giving recommendations to an executive, this Plant-Based Biologics Market report will surely help you to a degree.

Read Detailed Index of full Research Study @ https://www.absolutemarketsinsights.com/reports/Plant-Based-Biologics-2020-2028-791

Global plant-based biologics market is anticipated to grow at a CAGR of 26.45% over the forecast period. Byondis, eleva GmbH, Eversea Inc, iBio, Inc, Icon Genetics GmbH, InVitria, Kentucky BioProcessing, Inc., Leaf Expression Systems, Mapp Biopharmaceutical, Inc., Medicago Inc., OnePointOne, Inc., Pfizer Inc., Planet Biotechnology Inc., PlantForm, Protalix Biotherapeutics, Ventria Bioscience Inc., Zea Biosciences, amongst others.

Global Plant-Based Biologics Market:

  • By Clinical Trial
    • Phase I
    • Phase II
    • Others
  • By Source
    • Tobacco, tobacco cells, tobacco leaves
    • Nicotiana benthamiana leaves
    • Carrot cell culture
    • Rice seeds
    • Moss
    • Algae
    • Duckweed Leafy Biomass
    • Others
  • By Product
    • Taliglucerase alfa
    • ZMApp
    • PRX-102
    • HAI-05
    • Others
  • By Diseases
    • HIV/AIDS
    • Ebola virus
    • Cholera
    • Leprosy
    • Tuberculosis
    • Fabry Disease
    • Anthrax
    • Pompe Disease
    • Influenza
    • Type A
    • Type B
    • Type c
    • Alzheimer
    • Respiratory Syndromes
    • Gaucher disease
    • Cancer
    • Others
  • By Mode of Administration
    • Intramuscular
    • Oral Administration
    • Others
  • By End Users
    • Hospitals
    • Clinics
    • Primary Care Centers
    • Others
  • By Region:
    • North America
      • U.S.
      • Canada
      • Mexico
      • Rest of North America
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
        • Denmark
        • Finland
        • Iceland
        • Sweden
        • Norway
      • Benelux Union
        • Belgium
        • The Netherlands
        • Luxembourg
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • New Zealand
      • Australia
      • South Korea
      • Southeast Asia
        • Indonesia
        • Thailand
        • Malaysia
        • Singapore
        • Rest of Southeast Asia
      • Rest of Asia Pacific
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • Egypt
      • Kuwait
      • South Africa
      • Rest of Middle East & Africa
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America

Diseases have been affecting human civilizations since time immemorial. The global disease burden cost billions of dollars in revenue. Companies around the globe, both private and public, are increasingly trying to reduce the impact of diseases on human beings by developing both therapeutic and diagnostic biologics. Biologics, also called as biological drugs, is a product which is derived from living organisms, or contains some components of living organisms. Traditionally, animal-based biologics have been used for the treatment of diseases. Gelatin, for instance, is a partially hydrolysed collagen which is derived from bovine or porcine living organisms. Gelatin forms the basis of numerous capsule shells, and is also being used as a stabilizing agent in pharmaceutical products such as vaccines. However, religious practices and concerns regarding the humane treatment of animals for developing animal-based vaccines are prompting researches to move towards plant-based biologics. Furthermore, plant-based biologics are also economical to produce on a large scale, as compared to animal-based products. Also, these products have been proven to be effective agents in controlling pathogens, making it suitable for use as food additives.

Bacterial colicins, for instance, is derived from plants. Studies show that they can be used as a food additive for keeping food pathogenic bacteria at bay. Such factors are driving the adoption of plant-based biologics market. Escherichia coli strains, which causes food poisoning in human beings, are eliminated in the presence of these colicins in lower concentrations. The cost of manufacturing a gram of processed colicins is around US$ 1, which makes it viable for commercial use on a large scale. The U.S. Food and Drug Administration Agency has approved the use of these colicins in food products. Compared to the mammalian cell culture processes which are in use currently, plant-based biologics can be produced at a higher pace and greater quantity, without compromising on quality and efficiency. The rising demand for cost-effective drugs and food additives with minimal side effects, coupled with concerns regarding animal abuse for the development of drugs, is paving way for the growth of the global plant-based biologics market.

The COVID-19 pandemic has severely impacted the lives of individuals across the globe. Researches and academicians are increasingly trying to come up with innovative products which can tackle coronavirus. The mutation of the COVID-19 virus is raising concerns regarding the effectiveness of vaccines for controlling the spread of the virus. Plant-based biologics are being touted as a viable alternative for increasing the immunity in individuals, thereby making them more capable in fighting coronavirus. Furthermore, plant-based vaccines are also in development. Texas-based iBio, Inc., for instance, is focussing on the development of therapeutics and vaccines with plant-based products. ACE2-Fc is a COVID-19 therapeutic which is being developed by iBio, in partnership with Planet Biotech. Also, a couple of vaccines named IBIO-200 and IBIO-201 are in the final stages of development. IBIO-201 is based on a process that combines the antigens from SARS-CoV-2 spike protein and iBio’s LicKM molecule which helps in enhancing immune response in human beings. LicKM technology which is being used by iBio also has the potential of reducing vaccine antigen dose requirements in all age groups, thereby making it cost effective. Hence, the COVID-19 pandemic is expected to have a positive impact on the global plant-based biologics market in the coming years.

Key Questions Answered with this Study
1) What makes Plant-Based Biologics Market feasible for long term investment?
2) Know value chain areas where players can create value?
3) Teritorry that may see steep rise in CAGR & Y-O-Y growth?
4) What geographic region would have better demand for product/services?
5) What opportunity emerging territory would offer to established and new entrants in Plant-Based Biologics market?
6) Risk side analysis connected with service providers?
7) How influencing factors driving the demand of Plant-Based Biologics in next few years?
8) What is the impact analysis of various factors in the Plant-Based Biologics market growth?
9) What strategies of big players help them acquire share in mature market?
10) How Technology and Customer-Centric Innovation is bringing big Change in Plant-Based Biologics Market?

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Contact Name: Shreyas Tanna

Company: Absolute Markets Insights

Email Id: sales@absolutemarketsinsights.com

Phone: IN +91-7400-24-24-24, US +1-510-420-1213

Website: www.absolutemarketsinsights.com

Leave a Reply

Your email address will not be published. Required fields are marked *